Solid Biosciences Inc.
NASDAQ:SLDB
Overview | Financials
Company Name | Solid Biosciences Inc. |
Symbol | SLDB |
Currency | USD |
Price | 5.66 |
Market Cap | 218,448,832 |
Dividend Yield | 0% |
52-week-range | 2 - 15.05 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Alexander G. Cumbo |
Website | https://www.solidbio.com |
An error occurred while fetching data.
About Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candidate
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD